Try our Advanced Search for more refined results
Amgen Inc. et al v. Sanofi et al
Case Number:
1:14-cv-01317
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
August 29, 2019
Amgen Cholesterol Drug Patents Nixed, Undoing Jury Verdict
French drugmaker Sanofi scored a win Wednesday when a Delaware federal judge invalidated patents related to rival Amgen Inc.'s cholesterol-lowering drug Repatha, upending a February jury verdict that had gone largely in Amgen's favor.
-
February 25, 2019
Amgen's Cholesterol Drug Patents Are Valid, Jury Says
Patents related to Amgen Inc.'s cholesterol-lowering drug Repatha survived a challenge by rival pharmaceutical company Sanofi when a Delaware federal jury found largely in Amgen's favor Monday.
-
January 09, 2017
Sanofi Vows Appeal After Drug Injunction Stay Is Denied
Sanofi and its Regeneron Pharmaceuticals on Monday lost a bid to stay a permanent injunction of cholesterol-lowering drug Praluent ordered by a Delaware federal judge in a patent infringement suit brought by Amgen Inc., though the company has pledged to take the case to the Federal Circuit.
-
January 05, 2017
Amgen Wins Injunction On Sale Of Sanofi's Cholesterol Drug
Sanofi and Regeneron Pharmaceuticals must stop selling the cholesterol-lowering drug Praluent after a Delaware federal judge entered a permanent injunction in favor of Amgen Inc. on Thursday in a patent infringement suit brought by Amgen that saw a jury victory last year.
-
January 03, 2017
Jury Verdict Upheld In Amgen Cholesterol Drug Patent Row
An effort by drugmaker Sanofi to reverse a March jury verdict upholding cholesterol drug patents held by rival Amgen died Tuesday when a Delaware federal judge denied Sanofi's motions for judgment as a matter of law and for a new trial.
-
May 24, 2016
Sanofi Wants Jury Verdict Axed In Amgen Drug Patent Row
Sanofi urged a Delaware federal judge Monday to toss a jury's verdict finding rival Amgen's cholesterol drug patents valid and order a new trial or enter judgment against Amgen in its infringement row, saying the court erred in excluding evidence and throwing out Sanofi's obviousness defense.
-
May 13, 2016
Sanofi Says Evidence Doesn't Justify Verdict In Patent Suit
Sanofi-Aventis and Regeneron Pharmaceuticals Inc. pushed again Thursday for a Delaware federal judge to rule that the claims of two Amgen Inc. patents for a cholesterol drug were overbroad and insufficiently described after a jury found they were valid, saying the evidence admitted does not support the jury's findings..
-
April 27, 2016
Amgen Urges Ban On Cholesterol Drug Sales After Patent Win
Amgen Inc. urged a Delaware federal judge to levy a permanent injunction barring Sanofi SA and Regeneron Pharmaceuticals Inc. from selling cholesterol drug Praluent after a jury found Amgen's patents for the drug valid, according to a redacted filing Wednesday.
-
April 16, 2016
Sanofi Says Amgen Patents Doomed Despite Jury Win
A jury's finding that two Amgen patents for a cholesterol drug were valid can't stand, rival Sanofi told a Delaware federal court in a motion Friday, saying the claims of the patents are overbroad and insufficiently described.
-
March 16, 2016
Amgen Patents For Cholesterol Drug Valid, Jury Finds
A Delaware federal jury found that two Amgen Inc. patents for a cholesterol drug were valid, handing the California-based pharmaceutical giant victory over rivals Sanofi SA and Regeneron Pharmaceuticals Inc., Amgen said Wednesday.